Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Nahed El-Hassan to Cost-Benefit Analysis

This is a "connection" page, showing publications Nahed El-Hassan has written about Cost-Benefit Analysis.

 
Connection Strength
  
 
 
0.064
  
  1. Elhassan NO, Sorbero ME, Hall CB, Stevens TP, Dick AW. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med. 2006 Oct; 160(10):1070-6.
    View in: PubMed
    Score: 0.064
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.